# Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Source: https://onco.cc/trials/nct05112991/  
OnCo record `nct05112991` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Envafolimab, Lenvatinib in endometrial cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.

## Summary

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer is a phase 2 interventional study registered as NCT05112991 by 3D Medicines (Sichuan) Co., Ltd., with 108 participants planned, started 2022-03-04 and due to reach its primary completion in 2026-12. Interventions recorded: Envafolimab+Lenvatinib, Envafolimab. Conditions listed: Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05112991
- Phase: 2
- Setting: An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
- Sponsor: 3D Medicines (Sichuan) Co., Ltd.
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT05112991: https://clinicaltrials.gov/study/NCT05112991

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Envafolimab](https://onco.cc/drugs/envafolimab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05112991.json